Questionnaire and Laboratory Data on Vitiligo Vulgaris

NCT ID: NCT01206374

Last Updated: 2015-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-08-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Vitiligo Vulgaris
* Ability to sign consent

Exclusion Criteria

* Pregnant
* Inability to sign consent
* Inability to complete questionnaire
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beth Israel Medical Center

OTHER

Sponsor Role collaborator

St. Luke's-Roosevelt Hospital Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nanette Silverberg, MD

Role: PRINCIPAL_INVESTIGATOR

StLukesNY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology, Beth Israel Medical Center

New York, New York, United States

Site Status

Department of Dermatology, St. Luke's-Roosevelt Hospital Center

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010 Aug;22(4):445-52. doi: 10.1097/MOP.0b013e32833b6ac3.

Reference Type BACKGROUND
PMID: 20616733 (View on PubMed)

Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010 Jun;62(6):937-41. doi: 10.1016/j.jaad.2009.11.024.

Reference Type BACKGROUND
PMID: 20466170 (View on PubMed)

Pagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008 Jun;81(6):463-6.

Reference Type BACKGROUND
PMID: 18666385 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-027SLRHC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Leucotrichia in Vitiligo
NCT03402633 COMPLETED
Vitiligo, New Treatment and Serum s100B
NCT06768840 RECRUITING PHASE2/PHASE3